Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heartburn and arthritis drugs tested against COVID-19

NCT ID NCT05077332

Disease control Sponsor: Leidos Life Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tested whether combining famotidine (Pepcid) and celecoxib (Celebrex) could help people with COVID-19 recover faster. Only 4 participants were enrolled, making it too small to draw firm conclusions. The study aimed to see if these drugs could reduce symptom severity and prevent hospital visits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Famotidine (Pepcid) and celecoxib (Celebrex)
What this could lead to
If it works, this could point toward a safe, over-the-counter drug combination to help manage COVID-19 symptoms at home.
What could go wrong
This was a very small, early-phase trial with only 4 participants, so results are not reliable. The drugs may not work against COVID-19, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

4 people

The number who actually took part.

Started

Dec 2021

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* For eligibility criteria specific to the protocol, see: * Addendum #1 (LDOS-21-001-01) or * Addendum #2 (LDOS-21-001-02)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for 2019 novel coronavirus disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

2019 novel coronavirus disease 2019 novel coronavirus infection 2019-ncov disease 2019-ncov infection Coronavirus disease 2019 COVID -19 COVID-19 pandemic COVID-19 virus disease COVID-19 virus infection COVID19 SARS-CoV-2 acute respiratory disease SARS-CoV-2 infection

Contacts and locations

Locations

  • US02-04: Integrated Health Solutions

    Miami, Florida, 33126, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.